Trial Profile
Phase 1 trial of NOSO-95179 in patients with life-threatening multidrug-resistant Gram-negative infections
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2016
Price :
$35
*
At a glance
- Drugs NOSO 95179 (Primary)
- Indications Gram-negative infections; Nosocomial pneumonia
- Focus Adverse reactions; First in man
- 12 Jan 2016 New trial record
- 07 Dec 2015 According to Nosopharm media release, company to start IND-enabling studies in 2018 and launch our first-in-man clinical trial in 2019.